It's no secret that we need several companies' products to gain approval in order to meet worldwide demand for a coronavirus vaccine. Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) reached commercialization first when the U.S. Food and Drug Administration (FDA) granted their vaccine candidates Emergency Use Authorization (EUA) late last year. Johnson & Johnson (NYSE:JNJ), AstraZeneca (NASDAQ:AZN), and Novavax (NASDAQ:NVAX) are close behind. If each produced vaccines at top capacity, we still wouldn't have enough supply to immunize everyone worldwide. So, globally, there is plenty of business for all.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,